Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$7.64 +7.9%	$6.80	$5.81 ▼ $14.38	$631.67M	0.83	399,140 shs	603,873 shs
CATX Perspective Therapeutics	$3.68 +3.4%	$3.79	$1.60 ▼ $16.55	$273.29M	1.17	940,145 shs	579,561 shs
INFU InfuSystem	$9.57 -0.4%	$6.79	$4.61 ▼ $9.97	$196.29M	1.81	168,396 shs	167,703 shs
XENT Intersect ENT	$28.24	$28.24	$15.92 ▼ $28.25	$954.91M	1.45	351,526 shs	14,512 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	+7.91%	+3.66%	+18.08%	+17.00%	-16.23%
CATX Perspective Therapeutics	+3.37%	+1.94%	-15.40%	+53.97%	-75.89%
INFU InfuSystem	-0.42%	-0.62%	+60.57%	+76.89%	+38.70%
XENT Intersect ENT	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVS Bioventus	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	1.58 of 5 stars	3.6	1.0	0.0	0.0	2.0	0.8	0.0
INFU InfuSystem	3.6377 of 5 stars	2.0	5.0	0.0	0.0	3.3	4.2	1.9
XENT Intersect ENT	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	2.75	Moderate Buy	$13.75	79.97% Upside
CATX Perspective Therapeutics	3.18	Buy	$12.56	241.18% Upside
INFU InfuSystem	4.00	Strong Buy	$12.50	30.62% Upside
XENT Intersect ENT	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest XENT, BVS, CATX, and INFU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/21/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/12/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	BVS Bioventus	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$564.14M	1.12	$0.61 per share	12.58	$2.80 per share	2.73
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
INFU InfuSystem	$139.89M	1.40	$0.75 per share	12.79	$2.47 per share	3.87
XENT Intersect ENT	$106.75M	8.95	N/A	N/A	($2.06) per share	-13.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	-$156.23M	N/A	N/A	16.61	N/A	-7.11%	15.61%	4.01%	N/A
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	11/11/2025 (Estimated)
INFU InfuSystem	$870K	$0.23	159.53	30.87	N/A	1.12%	2.78%	1.41%	N/A
XENT Intersect ENT	-$159.63M	-$4.79	N/A	N/A	N/A	-161.94%	-709.52%	-48.18%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
INFU InfuSystem	N/A	N/A	N/A	N/A	N/A
XENT Intersect ENT	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	1.85	1.41	0.99
CATX Perspective Therapeutics	N/A	9.60	9.60
INFU InfuSystem	0.50	1.98	1.59
XENT Intersect ENT	6.89	1.88	1.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
CATX Perspective Therapeutics	54.66%
INFU InfuSystem	71.13%
XENT Intersect ENT	92.47%

Insider Ownership

Company	Insider Ownership
BVS Bioventus	33.00%
CATX Perspective Therapeutics	3.72%
INFU InfuSystem	11.40%
XENT Intersect ENT	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	1,200	82.68 million	54.46 million	Not Optionable
CATX Perspective Therapeutics	70	74.26 million	65.21 million	Optionable
INFU InfuSystem	410	20.43 million	19.10 million	Optionable
XENT Intersect ENT	433	33.81 million	33.10 million	Optionable

XENT, BVS, CATX, and INFU Headlines

Recent News About These Companies

Zee Ent. - Zee Entertainment Enterprises Share Price

August 2, 2024 | economictimes.indiatimes.com

Kiatnakin Bank PCL (KKP)

July 26, 2024 | investing.com

At the Intersection of Law & Policy

March 1, 2024 | slu.eduS

74-year-old woman killed in east Charlotte crash, CMPD says

December 6, 2023 | wsoctv.comW

What 4 Execs Want People To Know About the Intersection Between the Justice System and Behavioral Health

November 29, 2023 | medcitynews.comM

Traffic signal installed at notorious Riverside intersection where crash killed 8-year-old

November 4, 2023 | nbclosangeles.comN

Rogue Robotaxi Tries To Drive Down Footpath, Reverses Into Intersection

October 30, 2023 | jalopnik.comJ

XENT Historical Data

October 21, 2023 | investing.com

Video shows Brightline train goes through intersection while bars up; officials explain why

October 5, 2023 | tcpalm.comT

Intersection Into Proposed Cricket Stadium OK'd By Kendall Board

September 26, 2023 | patch.com

Music At The Intersection Festival Tells St. Louis’ Rich Musical History

September 12, 2023 | yahoo.com

4-way stop coming to Poinciana intersection where crash killed 4

September 12, 2023 | clickorlando.comC

Weaver intersection to finally open, Plainview close as extension work continues

September 9, 2023 | news-leader.comN

More social space, less traffic noise: The award-winning reno on a busy intersection

September 2, 2023 | smh.com.au

Code of conduct prepared for peace, intersect harmony during Muharram: Ayaz

August 31, 2023 | radio.gov.pkR

Euclid looking to increase safety at intersection following study

August 28, 2023 | news-herald.comN

Cruise car reportedly swerves in backhoe's way, is busted in SF intersection

August 28, 2023 | sfgate.com

Toronto is about to get a new type of intersection unlike any it's seen before

August 27, 2023 | blogto.comB

Watch: US Woman Points Gun At Cars On Intersection, Cop Drives Cruiser Into Her

August 19, 2023 | ndtv.comN

Lawsuit claims Iowa City teens were 'drag racing' when they struck Jennifer Russell's car in an intersection

July 19, 2023 | press-citizen.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENT, BVS, CATX, and INFU Company Descriptions

Bioventus NYSE:BVS

$7.64 +0.56 (+7.91%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.64 0.00 (-0.07%)

As of 08/22/2025 04:10 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Perspective Therapeutics NYSE:CATX

$3.68 +0.12 (+3.37%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.60 -0.08 (-2.20%)

As of 08/22/2025 08:00 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

InfuSystem NYSE:INFU

$9.57 -0.04 (-0.42%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.57 0.00 (0.00%)

As of 08/22/2025 05:40 PM Eastern

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Intersect ENT NASDAQ:XENT

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time